Combo IVD Market Progress Supported by Advancements in Point of Care Testing and Growing Need for Fast Accurate Multi Analyte Detection

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Combo IVD Market - (By Test Type (SARS-CoV-2 Flu A/B Combo Test, COVID-19, Influenza A/B, RSV Combo test, COVID-19 IgM/IgG Combo Test, HIV-1/2 Ag/Ab Combo Test, HIV/Syphilis Ab Combo Test, HIV, HBsAg, HCV & Syphilis Combo, hCG Combo Test, Thrombophilia Detection Combo Test, Other Test Types), By Testing, By End-User, By Channel, By Sample Type), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Combo IVD Market is valued at US$ 550.12 Mn in 2023, and it is expected to reach US$ 920.86 Mn by 2031, with a CAGR of 6.84% during the forecast period of 2024-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2376

Combo in vitro diagnostic (IVD) procedures involve the analysis of patient blood or tissue samples to evaluate key health indicators and support accurate diagnosis of various medical conditions. These diagnostics play a critical role in determining the most appropriate treatment pathways for individual patients. As the prevalence of both acute and chronic diseases continues to rise, the IVD sector is experiencing significant expansion. The growing incidence of long-term health conditions-including diabetes, cancer, cardiovascular disorders, and tuberculosis-along with a notable increase in infectious diseases, respiratory ailments, and gastrointestinal issues, is further amplifying the demand for advanced diagnostic solutions.

This escalating burden of disease is expected to accelerate the adoption of diagnostic equipment, thereby driving growth within the IVD market. Additionally, increased investment in research and development aimed at advancing cost-effective diagnostic technologies is creating new opportunities for market expansion. However, the high cost associated with diagnostic instruments and the ongoing maintenance requirements of testing systems remain key barriers that may constrain broader market growth.

List of Prominent Players in the Combo IVD Market:
• DRG International Inc.
• Becton, Dickinson and Company
• DiaCarta Inc
• Abbott Laboratories
• bioMérieux SA4
• Bio-Rad Laboratories
• Alpha IVD Srl
• BioGX BV
• Thermo Fisher Scientific Inc.
• Megna Health Inc
• CTK Biotech, Inc.
• Biopanda Reagents Ltd
• F. Hoffmann-La Roche Ltd
• Hologic Inc
• Siemens AG
• Other Prominent Players

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Market Dynamics
Drivers:
Growth in the combo IVD market is primarily driven by the expanding elderly population, which requires frequent health monitoring, and the continuous advancement of diagnostic technologies. Innovations in in vitro diagnostics-such as point-of-care (POC) testing, liquid biopsy, next-generation sequencing, and molecular diagnostics-are enhancing diagnostic accuracy, sensitivity, and turnaround time. These technological improvements have significantly contributed to better patient outcomes, thereby accelerating market adoption and overall sector expansion.

Challenges:
The market faces several notable challenges, including stringent regulatory requirements, a shortage of skilled professionals, and the absence of standardized protocols-particularly in emerging economies that experienced operational disruptions during lockdowns. Ethical considerations and strict regulations surrounding gene editing and human clinical research further restrict innovation and market entry. Additionally, unfavorable reimbursement environments and frequent changes in government policies continue to hinder industry growth.

The COVID-19 pandemic introduced widespread operational disruptions across the global IVD landscape. In response, service providers have implemented enhanced sanitization practices, reorganized work environments to improve resilience, and adopted digital collaboration tools to support remote customer engagement. As market conditions stabilize, IVD companies are increasingly leveraging digital technologies to expand their customer reach and improve operational efficiency.

Regional Trends:
North America is expected to maintain a substantial share of the combo IVD market, supported by the strong presence of key industry players and the ongoing development of advanced healthcare infrastructure. The high prevalence of chronic diseases-such as diabetes, cardiovascular conditions, and cancer-continues to drive demand for reliable diagnostic solutions across the region. Europe also accounts for a significant share of the market, driven by increased healthcare spending and the growing adoption of point-of-care diagnostic devices.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2376

Recent Developments:
• In Jan 2023, Bio-Rad Laboratories introduced the CFX Opus Deepwell Dx Real-Time PCR System. This system is a real-time PCR system that officially granted approval by the U.S. Food & Drug Administration (FDA) for in vitro diagnostic (IVD) testing. It has also been developed in compliance with the European Union's regulations for in vitro diagnostic medical devices.
• In June 2022, BD (Becton, Dickinson and Company) has notified the IVD directive 98/79/EC of the CE marking of the BD MAXTM Respiratory Viral Panel (RVP), a novel molecular diagnostic combination test that detects Respiratory Syncytial Virus (RSV), SARS-CoV-2, and Influenza A + B. A solitary nasal or nasopharyngeal biopsy sample was utilized in the test to ascertain whether a patient was infected with COVID-19, influenza, or RSV. This facilitated the prompt implementation of the appropriate treatment plan by clinicians and reduced the necessity for numerous tests or medical visits.

Segmentation of Combo IVD Market-
By Test Type-
• SARS-CoV-2 Flu A/B Combo Test
• COVID-19, Influenza A/B, RSV Combo test
• COVID-19 IgM/IgG Combo Test
• HIV-1/2 Ag/Ab Combo Test
• HIV/Syphilis Ab Combo Test
• HIV, HBsAg, HCV & Syphilis Combo
• hCG Combo Test
• Thrombophilia Detection Combo Test
• Other Test Types
By Testing -
• Rapid Testing
• Point Of Care Testing
By End-User-
• Diagnostics Centres
• Hospitals
• Homecare Setting
• Other End-Users
By Channel-
• Over-the-Counter
• Laboratory based
By Sample Type-
• Orals and Nasal Swabs
• Human Serum
• Whole Blood
• Other Sample Types
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/combo-ivd-market/2376

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.